Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Macrogenics Inc’s stock clocked out at $1.75, up 4.17% from its previous closing price of $1.68. In other words, the price has increased by $4.17 from its previous closing price. On the day, 0.66 million shares were traded. MGNX stock price reached its highest trading level at $1.815 during the session, while it also had its lowest trading level at $1.7.
Ratios:
To gain a deeper understanding of MGNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.92 and its Current Ratio is at 3.92. In the meantime, Its Debt-to-Equity ratio is 0.32 whereas as Long-Term Debt/Eq ratio is at 0.28.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 15 ’25 when Smith Beth Ann sold 423 shares for $2.56 per share. The transaction valued at 1,083 led to the insider holds 9,532 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGNX now has a Market Capitalization of 110408024 and an Enterprise Value of -53797936. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.74 while its Price-to-Book (P/B) ratio in mrq is 0.95. Its current Enterprise Value per Revenue stands at -0.359 whereas that against EBITDA is 0.522.
Stock Price History:
The Beta on a monthly basis for MGNX is 1.77, which has changed by -0.89309716 over the last 52 weeks, in comparison to a change of 0.09765589 over the same period for the S&P500. Over the past 52 weeks, MGNX has reached a high of $16.44, while it has fallen to a 52-week low of $0.99. The 50-Day Moving Average of the stock is -3.07%, while the 200-Day Moving Average is calculated to be -43.51%.
Shares Statistics:
It appears that MGNX traded 771.37K shares on average per day over the past three months and 709630 shares per day over the past ten days. A total of 62.82M shares are outstanding, with a floating share count of 58.00M. Insiders hold about 8.07% of the company’s shares, while institutions hold 81.91% stake in the company. Shares short for MGNX as of 1744675200 were 5338147 with a Short Ratio of 6.92, compared to 1741910400 on 4972906. Therefore, it implies a Short% of Shares Outstanding of 5338147 and a Short% of Float of 10.41.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Macrogenics Inc (MGNX) reflects the collective analysis of 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.71 and low estimates of -$0.71.
Analysts are recommending an EPS of between -$2.89 and -$2.89 for the fiscal current year, implying an average EPS of -$2.89.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $9.59M. It ranges from a high estimate of $26.55M to a low estimate of $1.6M. As of the current estimate, Macrogenics Inc’s year-ago sales were $9.1MFor the next quarter, 6 analysts are estimating revenue of $11.77M. There is a high estimate of $39.1M for the next quarter, whereas the lowest estimate is $1.6M.
A total of 6 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $174.34M, while the lowest revenue estimate was $21.2M, resulting in an average revenue estimate of $62.49M. In the same quarter a year ago, actual revenue was $149.96MBased on 4 analysts’ estimates, the company’s revenue will be $84.63M in the next fiscal year. The high estimate is $228.51M and the low estimate is $29.2M.
